BH 2012 - Scientific Program



Date	Time	Speaker	Title	Country
Mon 5	18:00-18:55	Peter Agre, Nobel Laureate on Chemistry, 2003	Aquaporin Water Channels: from Atomic Structure to Malaria
Mon 5	18:55-19:35	Luis Herrera	The Cuban Biotechnology Industry and the development of innovative products of high social impact

Date	Time	Speaker	Title	Country
Tue 6	8:30-9:15	Peter Roepstorff	Perspectives and current state of proteomics– are we heading in the right direction?
Wed 7	8:30-9:15		To be Announced

HIV Vaccine and Therapy

From	To	Speaker	Title	Country
9 :0	9 :40	Surita Roux	Design of phase 2b trials for HIV-1 vaccines in South Africa. Phambili trial as a case study	South Africa
9 :40	10:20	Enrique Iglesias	TERAVAC-HIV-1: A Multiantigenic vaccine candidate against HIV-1	Cuba
10:20	11:0	Luis E. Fernández	Neisseria containing GM3 ganglioside nanoparticles in the treatment of VIH positive individuals	Cuba
11:0	11:30	Ludger Ständker	Identification of an endogenous CXCR4 antagonist blocking X4 tropic HIV infection	Germany
11:30	12:0	Break
12:0	12:40	Luis Menéndez-Arias	Complex mutational patterns associated with resistance to HIV-1 reverse transcriptase inhibitors	Cuba
12:40	13:20	Vivian Kouri	Laboratory monitoring of HIV Subtypes and Antirretroviral (ARV) resistance in Cuba	Cuba
13:20	14:0	Jorge Pérez	Results of the antiretroviral therapy in Cuba	Cuba
14:0	14:30		Gereral Discussion

Dengue Vaccine

From	To	Speaker	Title	Country
9 :0	9 :25	Guadalupe Guzman	Dengue, the Cuban experience	Cuba
9 :25	9 :50	Glay Chinea	Design of beta-hairpin peptides with antiviral activity against Dengue	Cuba
9 :50	10:15	Vivian Huerta	Interaction with human plasma proteins reveals novel roles of domain III of Dengue virus E glycoprotein in viral infection	Cuba
10:15	10:40	Mabel Carabali	Dengue Vaccine Initiative	Colombia
10:40	11:5	Gerardo Guillen	Vaccines against dengue based on recombinant proteins	Cuba
11:5	11:30	Laura Lazo	Chimeric proteins P64k-DEN as vaccine candidates against dengue	Cuba
11:30	12:0	Break
12:0	12:25	Samantha Brandler	Dengue vaccine candidate based on measles virus vector and the DomIII of the envelope protein of dengue virus	France
12:25	12:50	Lisset Hermida	Capsid–based proteins as a subunit vaccine against dengue	Cuba
12:50	13:15	Roger Legrand	Prevention from Chikungunya virus experimental infection in macaques by live attenuated and replicating vaccine	France
13:15	13:40	Lazaro Gil	Alternative NHP species for dengue vaccine testing	Cuba
13:40	14:0		General Discussion

Glycomics Session “Dr. José Cremata”

From	To	Speaker	Title	Country
9 :0	9 :30		Posthumous tribute to Dr. José A. Cremata Álvarez	Ireland
9 :30	10:10	Pauline Rudd	State-of-the-art glycoanalytics for systems glycobiology, biomarker discovery and the pharmaceutical industry	Ireland
10:10	10:50	Louise Royle	Analysis of Glycosylation Critical Quality Attributes (CQAs)–which route to take?	United Kingdom
10:50	11:30	Pending
11:30	12:0	Break
12:0	12:40	Hans Kamerling	Unique a-D-glucan structures synthesized by novel bacterial trans-glucosylating enzymes	Netherlands
12:40	13:20	Ricardo Gutiérrez Gallego	Deciphering proteincarbohydrate interactions by SPR and CREDEX-MS	Spain
13:20	14:0		General Discussion

Cancer Biology and Treatment

From	To	Speaker	Title	Country
9 :30	10:0	Silvio Perea	CIGB-300 Anticancer Peptide: from Hypothesis to Clinical Research	Cuba
10:0	10:30	Jana Rolff	Detection of cancer biomarkers by the help of patient-derived xenografts	Germany
10:30	11:0	Joao Barata	Targeting aberrant signaling in T-cell acute leukemia	Portugal
11:0	11:30	Ananda Chakrabarty	Eradicating cancer in our life time: taking the first steps / 2nd Bacterial Proteins and Peptides in Cancer Therapy	USA
11:30	12:0	Break
12:0	12:30	Krishna Chakrabarty	BRCA1 gene mutations, breast cancer, therapeutic options and patent controversies	India
12:30	13:0	Singh Gurmit	Targeting Breast cancer induced bone metastasis	Canada
13:0	13:30	Carsten Peterson	Serum in primary breast cancer patients after surgery predicts the development of distant metastases	Sweden
13:30	14:0	Ananda Chakrabarty	Potential medical device for cancer therapy using live bacteria	USA

OMICs and Drug Design

From	To	Speaker	Title	Country
9 :30	10:0	Bruno Domon	New Approaches to Quantitative Proteomics	Luxembourg
10:0	10:30	Peter Roepstorff	Analysis of post translational protein modifications including glycosylation	Denmark
10:30	11:0	Lennard Martens	Driven by data: developments in computational proteomics	Belgium
11:0	11:30	Juan José Calvete	Venomics to fight a neglected pathology	Spain
11:30	12:0	Break
12:0	12:30	Bruno Domon	Application of Novel Targeted Proteomics Methods to Urinary Proteomics: Detection of Bladder Cancer Recurrence	Luxembourg
12:30	13:0	Peter Nilsson	A Human Protein Atlas - for proteomic antigen and antibody based plasma profiling	Sweden
13:0	13:30	Aniel Sánchez	Combination of MS and MS-MS proteomics. Dream or reality?	Cuba
13:30	14:0	Lázaro Betancourt	Selective Isolation of peptides by reversible chemical modification and ion exchange chromatography	Cuba

Infectious Diseases

From	To	Speaker	Title	Country
9 :0	9 :30	Camille Locht	Nasal vaccination with live attenuated B. pertussis against pertussis and other respiratory illnesses	France
9 :30	10:0	Verena L Muzio	Cuban pentavalent vaccines for the prevention of infectious diseases	Cuba
10:0	10:30	Gerardo Guillen	Virus Like Particle based adjuvants	Cuba
11:0	11:30	Abdelwahab Omri	Liposomes Drug Delivery System: Potentialities and Limitations in Infectious Diseases Applications	Canada
11:30	12:0	Break
12:0	12:30	Oliver Pérez	Shooting to some immunological paradigms using potent adjuvants	Cuba
12:30	13:0	Fernando Alberto Goldbaum	The BLS platform as a tool for the development of prophylactic and therapeutic vaccines	Argentina
13:0	13:15	Miriam Lastre	From Neisseria meningitidis serogroup B vaccine to Potent Adjuvants	Cuba
13:15	13:30	Belkis Romeu	AFCo1 provides nasal adjuvant activity against capsular polysaccharides of Neisseria meningitidis serogroup C and Salmonella Typhi	Cuba
13:30	13:45	Johanna Bernaldez	Isolation and characterization of toxins from a marine cone snails with effect in analgesic response	Mexico
13:45	14:0	Sven-Oliver Borchert	Optimization of an Integrated Bioprocess for production of potential Malaria vaccines with Pichia pastoris via Design of Experiments	Denmark
14:0	14:15	Mandana Behbahani	Antiherpetic Activity of Crude Extract and Fractions of Securigera securidaca (L.) Degen & Dorfl. Seeds, in Vitro	Iran
14:15	14:30	Rafael Sanchez	Adipose Tissue Derived-Mesenchymal Stem Cells Conditioned Medium Enhance Wound Healing	Colombia

Inflammation and Autoimmunity

From	To	Speaker	Title	Country
9 :30	10:0	Araceli Chico Capote	Expression of synovia in Rheumatoid arthritis	Cuba
10:0	10:30	Alicia Santos	A Proinflammatory Molecule Soluble Interleukin-15 Receptor alpha is increase in Rheumatoid Arthritis. Possible role in reverse signaling.	Cuba
10:30	11:0	Yannick Jacques	RLI, an improved version of Interleukin-15 as a promising candidate for tumor immunotherapy.	France
11:0	11:30	Martin F Bachmann	Cytos Immunostimulatory sequences packaged into virus-like particles for the treatment of asthma: Clinical efficacy and mechanism of action.	Switzerland
11:30	12:0	Break
12:0	12:30	Guillaume Darrasse-Jèze	DC–Treg checks and balances.	France
12:30	13:0	William van Eden	Stress protein Hsp70 family members are targets for disease suppressive long lived antigen specific Foxp3+ Treg	Netherlands
13:0	13:30	María del Carmen Domínguez	An altered peptide ligand derived from heat-shock protein 60 for treatment of Rheumatoid Arthritis.	Cuba
13:30	14:0	Daniele Ielo	The activity of phosphoinositide-3-kinase (PI3K) pathway is essential to define different CD4+ cellular responses and plays a critical role in autoimmunity.	Germany

Cancer Biology and Treatment

From	To	Speaker	Title	Country
9 :30	10:0	Fernando Alberto Goldbaum	Nanobodies as therapeutic agents in cancer and infectious diseases	Argentina
10:0	10:30	Jose L. Stephano	Application of llama recombinant antibodies	Mexico
10:30	11:0		To be Announced
11:0	11:30	Jorge Gavilondo	CIGB-166a: a novel anti-VEGF single chain Fv antibody fragment	Cuba
11:30	12:0	Break
12:0	12:30		To be Announced
12:30	13:0	Mónica Bequet	Experimental anti-metastatic effects of the VEGF-based cancer therapeutic vaccine CIGB-247	Cuba
13:0	13:30	Yanelys Morera	Immunogenicity and safety features of a novel VEGF-based cancer therapeutic vaccine CIGB-247	Cuba
13:30	14:0	Ana M. Vázquez	Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing-gangliosides: pre-clinical and clinical data	Cuba

OMICs and Drug Design

From	To	Speaker	Title	Country
9 :30	10:0	Vladimir Titorenko	Using a combination of chemical genomics, proteomics and lipidomics for discovery of natural anti-aging and anti-cancer compounds and defining mechanisms of their action	Canada
10:0	10:30	Isabel Guillen	Analysis of cell proliferation and gene expression profiles in EGF-treated tumor cell lines	Cuba
10:30	11:0	Emilio Cordova	The cancer chemopreventive pathway Nrf2-Keap1 plays a major role in cellular protection against arsenic exposure	Mexico
11:0	11:30	Harald Seitz	Identification of potential biomarkers after kidney transplantation	Germany
11:30	12:20	Break
12:0	12:30	Jochen Schewenk	Affinity proteomic profiling of plasma in aging and disease	Sweden
12:30	13:0	Carlos Cabal	Molecular imaging: Drug delivery, development and efficacy	Cuba
13:0	13:30	Bruno Domon	HUPO: The Human Proteome Project	Luxembourg

Infectious Diseases

From	To	Speaker	Title	Country
9 :30	10:0	Jean Dubuisson	Targeting hepatitis C virus entry for the development of new antiviral molecules	France
10:0	10:30	Arvind H. Patel	Virus-host interactions in hepatitis C virus infection	United Kingdom
10:30	11:0	Naglaa Shoukry	Innate and Adaptive Immune responses during Acute HCV Infection	Canada
11:0	11:30	Daniel Lamarre	Novel classes of HCV-specific inhibitors targeting membrane protein-protein interactions	Canada
11:30	12:0	Break
12:0	12:30	Shmuel Delgado	NS3/4A protease inhibitors: A new era in therapy of chronic hepatitis C	Israel
12:30	13:0	Santiago Dueñas-Carrera	Therapeutic vaccination against HCV: important or irrelevant in the antiviral era?	Cuba
13:0	13:30	Gillian Martínez-Donato	A vaccine candidate containing HCV structural proteins and NS3 induces neutralizing antibodies and multi-specific cellular immune response in animal models	Cuba
13:30	14:0	Maria Isaguliants	In vivo monitoring of immune response in preclinical trials of genetic vaccines	Russia

Neurodegenerative Diseases

From	To	Speaker	Title	Country
9 :30	10:0	Wolfgang Brück	New developments in the immunopathology of multiple sclerosis	Germany
10:0	10:30	Giselle Pentón.Rol	Molecular mechanisms associated to new therapies for multiple sclerosis and stroke	Cuba
10:30	11:0	Florian Kurschus	Phenotype, plasticity and pathogenicity of T helper cells in EAE the animal model for Multiple Sclerosis	Germany
11:0	11:30	Jorge Bergado	Neural plasticity, trophic factors and neurological restoration	Cuba
11:30	12:0	Break
12:0	12:30	Diana Garcia del Barco Herrera	Epidermal growth factor and growth hormone releasing peptide-6 coadministration: combined therapy for neurodegenerative diseases	Cuba
12:30	13:0		To be Announced
13:0	13:30	René Delgado	Neuroprotective efficacy of new tricyclic and tetracyclic molecules against experimental ischemia and neurovascular disorders.	Cuba
13:30	14:0	Daniel E. Amaro González	Neuro-EPO by Nasal Route as a Neurpprotective Therapy in Brain Ischemia	Cuba

Cancer Biology and Treatment

From	To	Speaker	Title	Country
8 :30	9 :0	Iraldo Bello	The development of new pharmaceutical formulation containing IFNs alpha and gamma for the treatment of Cancer	Cuba
9 :0	9 :30	Lorenzo Anasagasti	HeberPAG significantly prolongs the clinical response after the treatment of advanced non-melanoma skin cancer	Cuba
9 :30	10:0	Silvia Salva	Strategy for the treatment of brain tumors in Cuba	Cuba
10:0	10:30	Roberto Herrera	Outcomes of Glioma Surgery and iMRI	Argentina
10:30	11:0	Sieger Leenstra	Towards personalized treatment in neuro-oncology	Netherlands
11:0	11:30	Dania Vázquez	Molecular classification of glioblastoma and Novel therapies: perspective for a formulation containing IFNs alpha and gamma (CIGB-128) in a Cuban tumor- bearing sample	Cuba

OMICs and Drug Design

From	To	Speaker	Title	Country
8 :30	9 :0	Rainer Spang	Modeling cell perturbation data	Germany
9 :0	9 :30	Rodrigo Lopez	Integrating Biomolecular data into life science systems	United Kingdom
9 :30	10:0	Juan Antonio Vizcaino	What’s going on at EBI’s MS proteomics PRIDE database	United Kingdom
10:0	10:30	Ricardo Bringas	Building biological networks in gene-disease association studies	Cuba
10:30	11:0		To be Announced
11:0	11:30		To be Announced

Infectious Diseases

From	To	Speaker	Title	Country
8 :30	8 :50	Christian Trepo	Relevance of occult HBV infection	France
8 :50	9 :10	Mamun-Al-Mahtab	Clinical experience with NASVAC in Bangladeshi patients	Bangladesh
9 :10	9 :30	Ruskana Raihan	HBcAg expression in hepatocytes of chronic hepatitis B patients in Bangladesh	Bangladesh
9 :30	9 :50	Carla Montesano	HBV infection in Africa and prospective for preventing HBV infection in newborn	Italy
9 :50	10:10	Vittorio Colizzi	Hepatitis B vaccine co-formulation with the anti-tuberculosis vaccine	Italy
10:10	10:30	Pham Le Hoa	Virological and serological response in chronic Hepatitis B patients under PRE-S1/PRE-S2/S vaccine and lamiduvine combination treatment versus vaccine or lamivudine monotherapy	Vietnam
10:30	10:50		To be Announced	Italy